(GMRE) Global Medical REIT - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US37954A2042

Stock: Healthcare Facilities, Leasing

Total Rating 26
Risk 28
Buy Signal -0.17
REIT - Healthcare Facilities -17.1
Health Care REITs -17.8
Market Cap: 980m
Avg Trading Vol: 4.00M USD
ATR: 3.84%
Peers RS (IBD): 29.4
Risk 5d forecast
Volatility 34.2%
Relative Tail Risk -7.25%
Reward TTM
Sharpe Ratio -0.06
Alpha -15.73
Character TTM
Beta 0.514
Beta Downside 0.906
Drawdowns 3y
Max DD 39.20%
CAGR/Max DD 0.10

EPS (Earnings per Share)

EPS (Earnings per Share) of GMRE over the last years for every Quarter: "2021-03": 0.03, "2021-06": 0.04, "2021-09": 0.06, "2021-12": 0.06, "2022-03": 0.04, "2022-06": 0.03, "2022-09": 0.12, "2022-12": 0.01, "2023-03": 0.01, "2023-06": 0.18, "2023-09": 0.05, "2023-12": -0.01, "2024-03": 0.01, "2024-06": -0.05, "2024-09": 0.03, "2024-12": -0.04, "2025-03": 0.0103, "2025-06": -0.01, "2025-09": -0.0011, "2025-12": null,
EPS CAGR: -18.74%
EPS Trend: -48.5%
Last SUE: -0.07
Qual. Beats: 0

Revenue

Revenue of GMRE over the last years for every Quarter: 2021-03: 27.349, 2021-06: 28.261, 2021-09: 29.983, 2021-12: 30.343, 2022-03: 31.875, 2022-06: 33.697, 2022-09: 35.406, 2022-12: 36.306, 2023-03: 36.23, 2023-06: 36.351, 2023-09: 35.487, 2023-12: 32.931, 2024-03: 35.069, 2024-06: 34.214, 2024-09: 34.175, 2024-12: 34.952, 2025-03: 34.595, 2025-06: 37.88, 2025-09: 40.562, 2025-12: 35.171,
Rev. CAGR: 2.66%
Rev. Trend: 45.1%
Last SUE: 1.02
Qual. Beats: 3

Description: GMRE Global Medical REIT March 13, 2026

Global Medical REIT Inc. (GMRE) operates as a net-lease medical real estate investment trust. The company acquires healthcare facilities and leases them to healthcare providers, including physician groups and larger healthcare systems. This business model typically involves long-term leases with predictable income streams, a common characteristic of net-lease REITs where tenants are responsible for most property expenses.

GMRE is classified under the Health Care REITs GICS Sub Industry. Healthcare REITs specialize in owning and managing properties in the healthcare sector, such as hospitals, medical office buildings, and skilled nursing facilities. The demand for healthcare services generally remains stable, which can contribute to the resilience of this real estate sector.

To deepen your understanding of GMREs financial health, consider exploring its comprehensive profile on ValueRay.

Headlines to watch out for

  • Acquisitions of healthcare facilities fuel revenue growth
  • Lease rates and occupancy impact net operating income
  • Interest rate fluctuations affect borrowing costs
  • Healthcare industry trends influence tenant demand
  • Regulatory changes in healthcare sector pose risks

Piotroski VR‑10 (Strict, 0-10) 3.0

Net Income: -12.1m TTM > 0 and > 6% of Revenue
FCF/TA: -0.03 > 0.02 and ΔFCF/TA -4.19 > 1.0
NWC/Revenue: -454.2% < 20% (prev -472.6%; Δ 18.40% < -1%)
CFO/TA 0.06 > 3% & CFO 73.6m > Net Income -12.1m
Net Debt (-9.08m) to EBITDA (75.2m): -0.12 < 3
Current Ratio: 0.02 > 1.5 & < 3
Outstanding Shares: last quarter (13.4m) vs 12m ago 400.1% < -2%
Gross Margin: 67.86% > 18% (prev 0.79%; Δ 6.71k% > 0.5%)
Asset Turnover: 11.86% > 50% (prev 11.02%; Δ 0.85% > 0%)
Interest Coverage Ratio: 0.44 > 6 (EBITDA TTM 75.2m / Interest Expense TTM 35.1m)

Altman Z'' -4.90

A: -0.54 (Total Current Assets 16.3m - Total Current Liabilities 689.4m) / Total Assets 1.24b
B: -0.28 (Retained Earnings -350.0m / Total Assets 1.24b)
C: 0.01 (EBIT TTM 15.4m / Avg Total Assets 1.25b)
D: -0.48 (Book Value of Equity -343.9m / Total Liabilities 712.4m)
Altman-Z'' Score: -4.90 = D

Beneish M -3.00

DSRI: 0.88 (Receivables 7.22m/7.69m, Revenue 148.2m/138.4m)
GMI: 1.16 (GM 67.86% / 78.87%)
AQI: 1.00 (AQ_t 0.97 / AQ_t-1 0.98)
SGI: 1.07 (Revenue 148.2m / 138.4m)
TATA: -0.07 (NI -12.1m - CFO 73.6m) / TA 1.24b)
Beneish M-Score: -3.00 (Cap -4..+1) = AA

What is the price of GMRE shares?

As of March 24, 2026, the stock is trading at USD 33.84 with a total of 128,358 shares traded.
Over the past week, the price has changed by -0.53%, over one month by -5.05%, over three months by +3.42% and over the past year by -4.18%.

Is GMRE a buy, sell or hold?

Global Medical REIT has received a consensus analysts rating of 3.90. Therefore, it is recommended to buy GMRE.
  • StrongBuy: 4
  • Buy: 1
  • Hold: 5
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the GMRE price?

Issuer Target Up/Down from current
Wallstreet Target Price 40.9 20.7%
Analysts Target Price 40.9 20.7%

GMRE Fundamental Data Overview March 23, 2026

P/E Forward = 232.5581
P/S = 6.7651
P/B = 1.1194
P/EG = 5.0864
Revenue TTM = 148.2m USD
EBIT TTM = 15.4m USD
EBITDA TTM = 75.2m USD
Long Term Debt = 1.15m USD (from longTermDebt, last quarter)
Short Term Debt = 652.7m USD (from shortLongTermDebt, last quarter)
Debt = 728.7m USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = -9.08m USD (from netDebt column, last quarter)
Enterprise Value = 1.70b USD (979.8m + Debt 728.7m - CCE 9.08m)
Interest Coverage Ratio = 0.44 (Ebit TTM 15.4m / Interest Expense TTM 35.1m)
EV/FCF = -47.17x (Enterprise Value 1.70b / FCF TTM -36.0m)
FCF Yield = -2.12% (FCF TTM -36.0m / Enterprise Value 1.70b)
FCF Margin = -24.31% (FCF TTM -36.0m / Revenue TTM 148.2m)
Net Margin = -8.17% (Net Income TTM -12.1m / Revenue TTM 148.2m)
Gross Margin = 67.86% ((Revenue TTM 148.2m - Cost of Revenue TTM 47.6m) / Revenue TTM)
Gross Margin QoQ = 75.56% (prev 42.72%)
Tobins Q-Ratio = 1.37 (Enterprise Value 1.70b / Total Assets 1.24b)
Interest Expense / Debt = 1.15% (Interest Expense 8.40m / Debt 728.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = 12.2m (EBIT 15.4m * (1 - 21.00%))
Current Ratio = 0.02 (Total Current Assets 16.3m / Total Current Liabilities 689.4m)
Debt / Equity = 1.43 (Debt 728.7m / totalStockholderEquity, last quarter 509.8m)
Debt / EBITDA = -0.12 (Net Debt -9.08m / EBITDA 75.2m)
Debt / FCF = 0.25 (negative FCF - burning cash) (Net Debt -9.08m / FCF TTM -36.0m)
Total Stockholder Equity = 503.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.97% (Net Income -12.1m / Total Assets 1.24b)
RoE = -2.40% (Net Income TTM -12.1m / Total Stockholder Equity 503.9m)
RoCE = 3.05% (EBIT 15.4m / Capital Employed (Equity 503.9m + L.T.Debt 1.15m))
RoIC = 1.10% (NOPAT 12.2m / Invested Capital 1.11b)
WACC = 4.86% (E(979.8m)/V(1.71b) * Re(7.79%) + D(728.7m)/V(1.71b) * Rd(1.15%) * (1-Tc(0.21)))
Discount Rate = 7.79% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 125.8%
[DCF] Fair Price = unknown (Cash Flow -36.0m)
EPS Correlation: -48.55 | EPS CAGR: -18.74% | SUE: -0.07 | # QB: 0
Revenue Correlation: 45.09 | Revenue CAGR: 2.66% | SUE: 1.02 | # QB: 3
EPS next Year (2026-12-31): EPS=0.12 | Chg7d=+0.000 | Chg30d=-2.115 | Revisions Net=+0 | Growth EPS=-46.1% | Growth Revenue=+3.2%

Additional Sources for GMRE Stock

Fund Manager Positions: Dataroma | Stockcircle